Pressmeddelande -
Cereno Scientific obtains patents in 15 European countries solidifying CS1’s protection
..............................................................
GU Ventures sprider nyheter och information kring verksamheten, sina bolag, samt alumnibolag. Resterande pressmeddelande följer på engelska
..............................................................
Cereno Scientific (XSAT: CRNO B) today announced that CS1’s first patent family has been granted patents in 15 European countries following a completed validation and opposition period. This adds to the already granted markets that include Australia, Canada, Japan, and the US, thus securing patent protection for CS1 in nearly all global key markets.
“It is great to obtain our first patent for CS1 in Europe. Adding this market to the already granted markets offers a good broad patent protection, which is generally an important factor when looking at an asset’s commercial potential,” said Sten R. Sörensen, CEO at Cereno Scientific.
The granted European patent of Cereno’s first patent family, related to drug candidate CS1, is titled "Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors”, EP2683371. The European Patent Office (EPO) first conducted a coordinated search and evaluation on behalf of all member countries; following a positive response and subsequent patent issuance, Cereno selected the 15 key strategic markets in Europe to complete the registration of individual national patents in these markets.
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com
Ämnen
Kategorier
Regioner
About GU Ventures AB
GU Ventures builds businesses out of groundbreaking ideas that help shape a better tomorrow and is top-ranked by UBI Global Index as one of the world's 20 leading university-run incubators. We finance and develop new innovative business ideas with connections to the University of Gothenburg, which is one of northern Europe's largest universities. Our mission is commercialize the innovations, which leads to the utilization of research and skills, renewal of the business community, job creation and sustainable growth. Our passionate team of company builders, financial experts, IP and legal talent are dedicated supporters of our companies and ensure their successes. Since our starting point in 1995, GU Ventures has developed over 200 new business ideas of which 130 are in business today and of which 14 are listed. Our portfolio consists of 70 holdings and some projects. In the latest survey, 87% of companies match the global sustainability goals set by the UN. GU Ventures is wholly owned by the Swedish state and managed by the University of Gothenburg. Feel free to read more at: www.guventures.com.
